索拉非尼治疗晚期肝细胞性肝癌耐受性研究.doc

生堡塞坠处整盘查垫!Q生!Q旦筮22鲞筮!Q塑垦堑!』曼望!坚望:Q!鲤蛙!垫!Q:!尘:!!:丛!:!Q

・1535・
・临床研究・
索拉非尼治疗晚期肝细胞性肝癌的耐受性
研究
王俐稔钱建民汪防睿王乾伟

马震宇
【摘要】

目的探讨索拉非尼在临床治疗晚期原发性肝癌中的耐受性、安全性及相关疗效。
方法对2008年11月至2009年11月间于我院诊断晚期原发性肝癌接受索拉非尼治疗的患者的
相关临床数据进行分析,应用t检验及,检验。结果本研究16例患者,
月。治疗前Child评分A级者11例、B级3例、C级2例;治疗3个月后,治疔前A级患者中4例进
展至B级,B级中2例进展至c级。,(P>),
(P>)。治疗前Child ,B/C级患
(P>)。根据BCLC分期,,C/D级患者
。结论索拉非尼治疗可延长晚期肝细胞性肝癌的总生存期,并且在
不同肝功能状态的患者中均耐受性良好。
【关键词】索拉非尼;癌,肝细胞
Tolersn∞of sorafenib in the treatment of advanced hepatocellular carcinoma形tJ7、『G .
QIAN Jian-min,WANG Fang一枷,砺lⅣG Qian—wei,MA
Zhen・
of
General Surgery,Huashan
Hospital,Fudan University,Shanghai 2DD倒0,China
【Abstract】
Objective
To
evaluate tlle
tolerance。safety
and curative effect of sorafenib in the
treatment of advanced hepatocellular
carcinoma(HCC).Methods
The clinical data of 16
of
tients who
had been diagnosed
unresectable HCC from November 2008
November 2009
tively
The
survival
time


stratified according
Child—Push score,there were 11,3
and 2 patients in grades A,B,C respectively before the
month patient of grade A WaS transformed to B。and one of grade B to months later。4
patients of grade A was